StephenERubensteinMD

Oncology • Indianapolis, IN

Physician

Join to view full profile

Are you Dr. Rubenstein?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
You already have 60 invites waiting!
Read the latest clinical news, personalized to your specialty.

Claim this profile

Not you? Find your profile

Office
8111 S Emerson Ave
Suite 101
Indianapolis, IN 46237
Phone+1 317-859-5252

Fax+1 317-859-5258

Summary

Dr. Stephen Rubenstein, MD is an oncologist in Indianapolis, Indiana. He is currently licensed to practice medicine in Indiana, Virginia, and Maryland. He is affiliated with Franciscan Health Indianapolis, Indiana University Health University Hospital, and Select Specialty Hospital of INpolis.

Education & Training

SUNY Downstate Health Sciences UniversityFellowship, Hematology and Medical Oncology, 2005 - 2008
Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Residency, Internal Medicine, 2001 - 2004
Icahn School of Medicine at Mount Sinai/Beth IsraelResidency, Internal Medicine, 1971 - 1973
Chicago Medical School at Rosalind Franklin University of Medicine and ScienceClass of 1971

Certifications & Licensure

VA State Medical License 2023 - 2026
IN State Medical License 2010 - 2025
MD State Medical License 2018 - 2025
FL State Medical License 2008 - 2012
NY State Medical License 2004 - 2010
NJ State Medical License 2004 - 2009
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer Start of enrollment: 2011 Feb 14
Completed
Phase 3
Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma Start of enrollment: 2011 Apr 08
Active, not recruiting
Phase 2
A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2011 Oct 01
Completed
Phase 3
Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia Start of enrollment: 2013 Feb 12
Completed
Phase 3
Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin Lymphoma Start of enrollment: 2013 Jun 01
Completed
Phase 1, Phase 2
Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma Start of enrollment: 2013 Sep 16
Active, not recruiting
Phase 3
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
Completed
Phase 2
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
Completed
Phase 2, Phase 3
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
Active, not recruiting
Phase 3
Join now to see all